Vectura Group PLC (VEC) Rating Reiterated by Numis Securities Ltd

Vectura Group PLC (LON:VEC)‘s stock had its “buy” rating restated by investment analysts at Numis Securities Ltd in a research report issued on Friday. They currently have a GBX 225 ($2.78) price objective on the stock. Numis Securities Ltd’s target price would indicate a potential upside of 42.95% from the stock’s previous close.

VEC has been the topic of several other research reports. JPMorgan Chase & Co. reissued an “overweight” rating on shares of Vectura Group PLC in a research report on Tuesday, January 17th. N+1 Singer cut their target price on Vectura Group PLC from GBX 208 ($2.57) to GBX 202 ($2.49) and set a “buy” rating on the stock in a research report on Tuesday, December 20th. Peel Hunt reissued a “buy” rating and set a GBX 200 ($2.47) target price on shares of Vectura Group PLC in a research report on Wednesday, January 25th. Stifel Nicolaus reissued a “buy” rating and set a GBX 225 ($2.78) target price on shares of Vectura Group PLC in a research report on Tuesday, January 24th. Finally, FinnCap reissued a “buy” rating and set a GBX 225 ($2.78) target price on shares of Vectura Group PLC in a research report on Tuesday, November 29th. Seven research analysts have rated the stock with a buy rating, Vectura Group PLC presently has an average rating of “Buy” and an average price target of GBX 220.29 ($2.72).

Analyst Recommendations for Vectura Group PLC (LON:VEC)

Vectura Group PLC (LON:VEC) opened at 157.40 on Friday. The firm’s market capitalization is GBX 904.58 million. The stock’s 50 day moving average price is GBX 144.08 and its 200 day moving average price is GBX 139.84. Vectura Group PLC has a 52 week low of GBX 122.90 and a 52 week high of GBX 179.00.

Your IP Address:

Vectura Group PLC Company Profile

Vectura Group plc is engaged in research, development and commercialization of therapeutic products and drug delivery systems for human use. The Company’s products include Ultibro Breezhaler (European Union (EU) and Rest of World (RoW)) – LABA-LAMA; Seebri Breezhaler (EU and RoW) – LAMA; AirFluSal Forspiro (EU and RoW) – ICS-LABA; ADVATE (Global) – Antihaemophilic Factor (Recombinant); Adept (Global) – Icodextrin; Anoro Ellipta (Global) – LAMA-LABA; Relvar Ellipta/Breo Ellipta (Global) – ICS-LABA, and Incruse Ellipta (Global) – LAMA.

Receive News & Ratings for Vectura Group PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vectura Group PLC and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Nike Suspends Relationship with Maria Sharapova
Nike Suspends Relationship with Maria Sharapova
Rob Bironas Ex-Titans Kicker Dies in Car Crash
Rob Bironas Ex-Titans Kicker Dies in Car Crash
Ron Washington Leaves Texas Rangers Due to an Affair
Ron Washington Leaves Texas Rangers Due to an Affair
Jonathan Dwyer Falls in Line with Other Banned NFL Players
Jonathan Dwyer Falls in Line with Other Banned NFL Players
Tony Stewart Case Going to the Grand Jury
Tony Stewart Case Going to the Grand Jury
Oscar Pistorius “Blade Runner” Found Not Guilty of Murder
Oscar Pistorius “Blade Runner” Found Not Guilty of Murder


Leave a Reply

 
© 2006-2017 Web Breaking News.